Sodium valproate

Sodium valproate
Sodium valproate
Systematic (IUPAC) name
sodium 2-propylpentanoate
Clinical data
AHFS/ monograph
MedlinePlus a682412
Pregnancy cat. D(AU) D(US)
Legal status Prescription only
Routes Oral, i.v.
Pharmacokinetic data
Protein binding 90–95%
Metabolism 75% by CYP enzymes
Half-life 9–18 hours
Excretion 20% excreted as glucuronide
CAS number 1069-66-5 YesY
ATC code N03AG01
PubChem CID 14047
ChemSpider 13428 YesY
KEGG D00710 YesY
Chemical data
Formula C8H15NaO2 
Mol. mass 166.20 g/mol
SMILES eMolecules & PubChem
 N(what is this?)  valproate (verify)

Sodium valproate (INN) or valproate sodium (USAN) is the sodium salt of valproic acid and is an anticonvulsant used in the treatment of epilepsy, anorexia nervosa, panic attack, anxiety disorder, posttraumatic stress disorder, migraine and bipolar disorder, as well as other psychiatric conditions requiring the administration of a mood stabilizer. Sodium valproate can be used to control acute episodes of mania and acute stress reaction. Side effects can include tiredness, tremors, nausea, vomiting and sedation.[1] The intravenous formulations are used when oral administration is not possible.

In pregnancy, valproate has the highest risk of birth defects of any of the commonly-used antiepilepsy drugs. However, some epilepsy can only be controlled by valproate, and seizures also pose grave risk to mother and child.

Some of the common adverse effects include: tiredness, tremor, sedation and gastrointestinal disturbances. In addition, about 10% of the users experience reversible hair loss. [2]



Trade names are in bold, followed by the manufacturer.


  • Intravenous injection – Depacon by Abbott Laboratories.
  • Syrup – Depakene by Abbott Laboratories. (Note Depakene capsules are valproic acid).
  • Depakote tablets are a mixture of sodium valproate and valproic acid.



  • Tablets – Orlept by Wockhardt and Epilim by Sanofi-Aventis.
  • Oral solution – Orlept Sugar Free by Wockhardt and Epilim by Sanofi-Aventis.
  • Syrup – Epilim by Sanofi-Aventis.
  • Intravenous injection – Epilim Intravenous by Sanofi-Aventis.
  • Extended release tablets – Epilim Chrono by Sanofi-Aventis. A combination of sodium valproate and valproic acid in a 2.3:1 ratio.
  • Enteric-coated tablets – Epilim EC200 by Sanofi-synthélabo. A 200 mg sodium valproate enteric-coated tablet.

UK only

  • Capsules – Episenta prolonged release by Beacon.
  • Sachets – Episenta prolonged release by Beacon.
  • Intravenous solution for injection – Episenta solution for injection by Beacon.

Germany, Switzerland, Norway, Finland

  • Tablets – Orfiril by Desitin Pharmaceuticals
  • Intravenous injection – Orfiril IV by Desitin Pharmaceuticals

South Africa

  • Syrup – Convulex by Byk Madaus
  • Tablets – Epilim by sanofi~synthelabo



  • Tablets – Depakene by Kyowa Hakko Kirin.
  • Extended release tablets – Depakene-R by Kyowa Hakko Kogyo and Selenica-R by Kowa.
  • Syrup – Depakene by Kyowa Hakko Kogyo.


In much of Europe, Depakine and Depakine Chrono (tablets) are equivalent to Epilim and Epilim Chrono above.


Safety in pregnancy

The risk of birth defects with valproate is two to five times higher than other frequently-used anti-epileptic drugs (absolute rates of birth defects 6-11%). Children born to mothers using valproate have significantly lower I.Q. scores (9 points). However, some epilepsy can only be controlled by valproate, and seizures during pregnancy can have grave consequences for both mother and child. Doctors recommend that women who intend to become pregnant should be switched to a different drug using combined therapy if possible, which takes several months. Women who are already pregnant and taking a high dose of valproate should try to lower their dose.[3][4][5]

All antiepileptic medications have been shown to be associated with higher risks of fetal abnormalities (mostly for spina bifida) since at least 1983 with the risks being related to the strength of medication used and use of more than one drug[6][7]

Valproate has also been recognised as sometimes causing a specific facial changes ("facial phenotype") termed "fetal valproate syndrome".[8] Sodium valproate has been associated with the rare condition paroxysmal tonic upgaze of childhood, also known as Ouvrier-Billson syndrome, from childhood or fetal exposure (this condition resolved after discontinuing valproate therapy.[9][10]

While developmental delay is usually associated with altered physical characteristics (dysmorphic features), this is not always the case.[11]

A 2005 study found rates of autism among children exposed to sodium valproate before birth in the cohort studied were 8.9%.[12] The normal incidence for autism in the general population is estimated at less than one percent.[13] It has been suggested that Valproate may best be avoided in women with localisation epilepsy, where there are more effective and less risky alternatives such as carbamazepine.[11] A 2008 study [14] also suggested a correlation between higher rates of autism in children whose mothers were treated for seizure disorders during pregnancy using sodium valproate (less than 1% for children who didn't receive the drug in vitro vs. 6.3% for children who did). However, only 632 children were followed in this study, prompting criticism that this study was too small to rely on to say whether there was a definitive correlation between the use of sodium valproate in pregnant mothers and higher autism rates in their children, or whether other anti-seizure medications used during pregnancy don't cause this effect.

One multi-centre trial in the UK and US looked at cognitive function in 309 children born to mothers with epilepsy and found that sodium valproate-use was associated with an IQ level eight points lower in children born to mothers taking sodium valproate than mothers taking other anti-epileptic drugs.[15] The authors of the study attempted to correct for confounding factors, but this is an observational study, and therefore cannot prove a causal link. It should be noted, however, that to prove a causal link requires a randomised-controlled trial, which is not possible to perform.[16] It is therefore unlikely that any stronger evidence will become available.

A class action is currently underway in the United Kingdom regarding the claim that the drug used in pregnancy caused a range of problems in children, including autism, learning and social difficulties, ADHD, spinal stenosis,[specify] facial abnormalities, vision defects, dyslexia, dyspraxia, delayed speech and motor development.[17][18][19]

See also


  1. ^ Gelder, M., Mayou, R., Geddes, J. (2006) Psychiarty. 3rd edition. Oxford: Oxford University Press
  2. ^ Gelder, M, Mayou, R. and Geddes, J. 2005. Psychiatry. 3rd ed. New York: Oxford. pp250.
  3. ^ I.Q. Harmed by Epilepsy Drug in Utero By RONI CARYN RABIN, New York Times, April 15, 2009
  4. ^ Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs, Kimford J. Meador et al. for the NEAD Study Group, N Engl J Med 360:1597 April 16, 2009
  5. ^ Which drug for the pregnant woman with epilepsy? Torbjorn Tomson, N Engl J Med 360:1597 April 16, 2009
  6. ^ Koch S, Göpfert-Geyer I, Jäger-Roman E, et al. (February 1983). "[Anti-epileptic agents during pregnancy. A prospective study on the course of pregnancy, malformations and child development]" (in German). Dtsch. Med. Wochenschr. 108 (7): 250–7. doi:10.1055/s-2008-1069536. PMID 6402356. 
  7. ^ Moore SJ, Turnpenny P, Quinn A, et al. (July 2000). "A clinical study of 57 children with fetal anticonvulsant syndromes". J. Med. Genet. 37 (7): 489–97. doi:10.1136/jmg.37.7.489. PMC 1734633. PMID 10882750. 
  8. ^ DiLiberti JH, Farndon PA, Dennis NR, Curry CJ (November 1984). "The fetal valproate syndrome". Am. J. Med. Genet. 19 (3): 473–81. doi:10.1002/ajmg.1320190308. PMID 6439041. 
  9. ^ Epileptic Disord. 2007 Sep; 9(3):332-6
  10. ^ J Child Neurol. 1988 Jul;3(3):177-80
  11. ^ a b Adab N, Kini U, Vinten J, et al. (November 2004). "The longer term outcome of children born to mothers with epilepsy". J. Neurol. Neurosurg. Psychiatr. 75 (11): 1575–83. doi:10.1136/jnnp.2003.029132. PMC 1738809. PMID 15491979. "This argues that the fetal valproate syndrome constitutes a real clinical entity that includes developmental delay and cognitive impairments, but that some children might exhibit some developmental delay without marked dysmorphism." 
  12. ^ Rasalam AD, Hailey H, Williams JH, et al. (August 2005). "Characteristics of fetal anticonvulsant syndrome associated autistic disorder". Dev Med Child Neurol 47 (8): 551–5. doi:10.1017/S0012162205001076. PMID 16108456. 
  13. ^ Autism Society of America: About Autism
  14. ^ Bromley L, Mawer G, Clayton-Smith J, Baker GA, et al. (December 2008). "Autism spectrum disorders following in utero exposure to antiepileptic drugs". Neurology 71 (23): 1923–4. doi:10.1212/01.wnl.0000339399.64213.1a. PMID 19047565. 
  15. ^ Meador KJ, Baker GA, Browning N, et al. (2009). "Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs". N Engl J Med 360 (16): 1597–1605. doi:10.1056/NEJMoa0803531. PMC 2737185. PMID 19369666. 
  16. ^ Tomson T (2009). "Which drug for the pregnant woman with epilepsy?". N Engl J Med 360 (16): 1667–1669. doi:10.1056/NEJMe0901550. PMID 19369673. 
  17. ^ Families Sue Europe’s Largest Drug Company Over Anti-Convulsant Drug as Deadline Is Given By High Court
  18. ^ "Legal action over Epilim". Epilepsy Action. 24 April 2007. Retrieved 15 April 2009. 
  19. ^ Brimelow A (1 October 2004). "Women sue over epilepsy drug risk". BBC News. Retrieved 15 April 2009. 

External links

Wikimedia Foundation. 2010.

Игры ⚽ Поможем написать курсовую

Look at other dictionaries:

  • sodium valproate — n the sodium salt C8H15NaO2 of valproic acid used as an anticonvulsant called also valproate sodium * * * an anticonvulsant drug used to treat all types of epilepsy. It is administered by mouth; side effects may include digestive upsets,… …   Medical dictionary

  • sodium valproate — an anticonvulsant drug used to treat all types of epilepsy. It is administered by mouth or intravenously; side effects may include digestive upsets, weight gain, and (rarely) impaired liver function. It should be used with caution in pregnant… …   The new mediacal dictionary

  • valproate sodium — n SODIUM VALPROATE * * * val·pro·ate so·di·um (val proґāt) the sodium salt of valproic acid, having the same uses as the parent compound …   Medical dictionary

  • valproate — /valˈprō āt/ noun Any salt of valˈproic acid (C8H16O2), esp sodium valproate, used to treat epilepsy and bipolar disorder …   Useful english dictionary

  • Valproate semisodium — Main article: Valproic acid Valproate semisodium (INN) or divalproex sodium (USAN) consists of a compound of sodium valproate and valproic acid in a 1:1 molar relationship in an enteric coated form. It is used in the United Kingdom, Canada, and… …   Wikipedia

  • valproate — val·pro·ate val prō .āt n a salt or ester of valproic acid esp SODIUM VALPROATE …   Medical dictionary

  • Натрия Вальпроат (Sodium Valproate) — противосудорожное средство; применяется для лечения всех видов эпилепсии. Назначается внутрь; возможные побочные эффекты: расстройства процесса пищеварения, сонливость и нарушение мышечной координации. Торговое название: эпилим (Epilim). Источник …   Медицинские термины

  • Valproate de sodium — Acide valproïque Acide valproïque Général No CAS …   Wikipédia en Français

  • Valproate — Acide valproïque Acide valproïque Général No CAS …   Wikipédia en Français

  • divalproex sodium — Pentanoic acid, 2 propyl , sodium salt (2:1); an anticonvulsant used in absence seizures and related seizure disorders. Derived from valproic acid. * * * di·val·pro·ex sodium .dī val prō eks , .val prō n a coordination compound of valproate and… …   Medical dictionary

Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”